Home
    • Plans Blog Contact
    Nu-Med Plus, Inc. logo

    Nu-Med Plus, Inc.

    NUMD
    Last price US$0.0184
    Market cap US$1.5m
    12M price change -63.20%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Abbott LaboratoriesABT Industry peer DexCom IncDXCM Industry peer Edwards Lifesciences CorpEW Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Nu-Med Plus, Inc. Overview

    Industry: Medical Devices

    Sector: Healthcare

    Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. The company develops a hospital nitric oxide delivery system, a clinical nitric oxide delivery system, a mobile rechargeable device to deliver nitric oxide gas, and a nitric oxide system that can be used for research applications. It serves hospitals, health systems, and the medical community. The company was incorporated in 2011 and is based in New York, New York. Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. The company develops a hospital nitric oxide delivery system, a clinical nitric oxide delivery system, a mobile rechargeable device to deliver nitric oxid Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Nu-Med Plus, Inc. into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 14, 2026

    Quarterly result summary

    Latest company-filed earnings material is available for source review.

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    SEC filing Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing ANNUAL REPORT ON FORM 10K FOR THE YEAR ENDED DECEMBER 31, 2025 Apr 15, 2026 SEC filing QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED SEPTEMBER 30, 2025 Nov 14, 2025 SEC filing QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED JUNE 30, 2025 Aug 11, 2025 SEC filing QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED MARCH 31, 2025 May 22, 2025 SEC filing ANNUAL REPORT ON FORM 10K FOR THE YEAR ENDED DECEMBER 31, 2024 Mar 31, 2025 SEC filing QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED SEPTEMBER 30, 2024 Nov 14, 2024 SEC filing QUARTERLY REPORT ON FORM 10Q FOR THE QUARTER ENDED JUNE 30, 2024 Aug 21, 2024

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    No qualified company news in the last 14 days

    No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

    Earnings Per Share

    Score 2.00/5
    Nu-Med Plus, Inc. earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

    Return on Equity

    Score 2.81/5
    Nu-Med Plus, Inc. stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Nu-Med Plus,... NUMD US$1.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    Nu-Med Plus, Inc. olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Nu-Med Plus,... NUMD US$1.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

    Leverage

    Score 3.44/5
    Nu-Med Plus, Inc. attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Nu-Med Plus,... NUMD US$1.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Nu-Med Plus, Inc. logo

    Nu-Med Plus, Inc.

    US$0.0184

    US$1.5m

    0.00%

    -63.20%